Beyond the Tumor Mass: From Initiating Clones to Overt Isocitrate Dehydrogenase-Mutant Gliomas
DNA and Cell Biology · 2026
DOI: 10.1177/10445498261435336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift DNA and Cell Biology, 2026. Verfasst von Jung Won Park und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Mutation, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korea Health Industry Development Institute.
Abstract (Originalsprache)
Isocitrate dehydrogenase ( IDH )-mutant gliomas are primary malignant brain tumors defined by recurrent mutations in IDH1/2 genes and characterized by distinct molecular subtypes and relatively favorable clinical outcomes. Although these mutations represent early and defining events, recent data suggest that IDH1 mutant glial progenitor cells can reside within the histologically normal-appearing peritumoral cortex, indicating that cells harboring the founding driver mutation can persist beyond the tumor mass while retaining nonmalignant features. These observations challenge a purely gene-centric view of gliomagenesis. In this essay, we review emerging data supporting a multistep and context-dependent model in which the mutant IDH enzyme establishes an epigenetically altered cellular state, with subsequent genetic alterations and lineage-specific constraints that shape malignant progression. We further discuss the conceptual distinction between the “cell-of-mutation” and the “cell-of-origin” and consider how temporal stratification of tumor evolution may inform stage-specific therapeutic strategies along the transition from initiating clones beyond the tumor mass to overt tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
- Sovargen Inc., Daejeon, Republic of Korea.
- Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Neurosurgery, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Seok-Gu Kang
Förderung
- National Research Foundation of Korea
- Korea Health Industry Development Institute
Zitieren
APA
Park, J. W., Lee, J. H., & Kang, S. G. (2026). Beyond the Tumor Mass: From Initiating Clones to Overt Isocitrate Dehydrogenase-Mutant Gliomas. DNA and Cell Biology. https://doi.org/10.1177/10445498261435336
Vancouver
Park JW, Lee JH, Kang SG. Beyond the Tumor Mass: From Initiating Clones to Overt Isocitrate Dehydrogenase-Mutant Gliomas. DNA and Cell Biology. 2026. doi:10.1177/10445498261435336
BibTeX
@article{Park2026,
author = {Park, Jung Won and Lee, Jeong Ho and Kang, Seok-Gu},
title = {Beyond the Tumor Mass: From Initiating Clones to Overt Isocitrate Dehydrogenase-Mutant Gliomas},
journal = {DNA and Cell Biology},
year = {2026},
doi = {10.1177/10445498261435336}
}
EUVIMED